2024
Association of Social Support and Health Status Outcomes in Peripheral Artery Disease
Callegari S, Romain G, Cleman J, Scierka L, Peri-Okonny P, Spertus J, Labrosciano C, Beltrame J, Abbott J, Fitridge R, Mena-Hurtado C, Smolderen K. Association of Social Support and Health Status Outcomes in Peripheral Artery Disease. Journal Of Vascular Surgery 2024 PMID: 39151740, DOI: 10.1016/j.jvs.2024.08.010.Peer-Reviewed Original ResearchENRICHD Social Support InventoryLow social supportLow perceived social supportGeneric health statusHealth status outcomesPeripheral arterial diseaseSocial supportHealth statusBiopsychosocial variablesStatus outcomesAssociation with health status outcomesAssociated with lower health statusDisease-specific health statusBaseline perceived social supportImprove social supportLower health statusSocial Support InventoryImprove health statusPerceived social supportDisease-specificEQ-5D-3LCare of patientsQuality of lifeEQ-5D-3L indexBiopsychosocial factors
2023
Patient knowledge and preferences for peripheral artery disease treatment
Smolderen K, Romain G, Gosch K, Arham A, Provance J, Spertus J, Poosala A, Shishehbor M, Safley D, Scott K, Stone N, Mena-Hurtado C. Patient knowledge and preferences for peripheral artery disease treatment. Vascular Medicine 2023, 28: 397-403. PMID: 37638882, PMCID: PMC10591804, DOI: 10.1177/1358863x231181613.Peer-Reviewed Original ResearchPeripheral artery diseaseTreatment goalsPatient knowledgeTreatment optionsTreatment preferencesHeart attack/strokeSymptomatic peripheral artery diseasePeripheral artery disease treatmentImportant treatment goalQuality of lifeCost of treatmentSpecific treatment goalsMulticenter registryPAD symptomsPain reliefSecondary preventionArtery diseaseTreatment choiceTreatment benefitPatient understandingPatientsMedical decision makingDisease managementClaudicationDisease treatment
2021
Association of sleep apnea with outcomes in peripheral artery disease: Insights from the PORTRAIT study
Jelani QU, Mena-Hurtado C, Gosch K, Mohammed M, Labrosciano C, Regan C, Scierka LE, Spertus JA, Nagpal S, Smolderen KG. Association of sleep apnea with outcomes in peripheral artery disease: Insights from the PORTRAIT study. PLOS ONE 2021, 16: e0256933. PMID: 34506511, PMCID: PMC8432750, DOI: 10.1371/journal.pone.0256933.Peer-Reviewed Original ResearchConceptsPeripheral artery diseasePeripheral Artery QuestionnaireSleep apneaHealth statusArtery diseaseSummary scoresDisease-specific Peripheral Artery QuestionnaireFive-year survival curvesHigh ankle-brachial indexPAQ summary scoreVascular specialty clinicsAnkle-brachial indexLog-rank testSleep apnea statusHealth status outcomesWorse health statusQuality of lifeBetter health statusCause mortalityMultivariable adjustmentPAD symptomsCoronary diseasePeripheral interventionsUS patientsMean ageTreatment decisions for patients with peripheral artery disease and symptoms of claudication: Development process and alpha testing of the SHOW-ME PAD decision aid
Smolderen KG, Pacheco C, Provance J, Stone N, Fuss C, Decker C, Bunte M, Jelani QU, Safley DM, Secemsky E, Sepucha KR, Spatz ES, Mena-Hurtado C, Spertus JA. Treatment decisions for patients with peripheral artery disease and symptoms of claudication: Development process and alpha testing of the SHOW-ME PAD decision aid. Vascular Medicine 2021, 26: 273-280. PMID: 33627058, PMCID: PMC8169642, DOI: 10.1177/1358863x20988780.Peer-Reviewed Original ResearchConceptsPeripheral artery diseaseArtery diseaseTreatment optionsSymptoms of claudicationInvasive treatment optionNon-invasive treatmentQuality of lifeClaudication symptomsClaudication treatmentPatient knowledgeSpecialty careTreatment decisionsDecision aidPatientsCliniciansDecisional needsInternational Patient Decision Aid Standards criteriaStandard criteriaPrototype decision aidImplementation logisticsSymptomsDecisional qualityDiseaseTreatmentClaudication
2020
Cilostazol and peripheral artery disease-specific health status in ambulatory patients with symptomatic PAD
Mohammed M, Gosch K, Safley D, Jelani QU, Aronow HD, Mena C, Shishehbor MH, Spertus JA, Abbott JD, Smolderen KG. Cilostazol and peripheral artery disease-specific health status in ambulatory patients with symptomatic PAD. International Journal Of Cardiology 2020, 316: 222-228. PMID: 32464249, DOI: 10.1016/j.ijcard.2020.05.042.Peer-Reviewed Original ResearchConceptsPeripheral Artery QuestionnaireHealth statusDisease-specific health statusPatient-reported health statusHeart failure historyNon-cilostazol groupUse of cilostazolPAQ scoresImprovement of symptomsSubsequent health statusQuality of lifeCilostazol therapyCilostazol useSymptomatic PADPatient characteristicsPharmacological optionsAmbulatory patientsLimitation scoresMean ageFunctional statusUS cohortTreatment goalsSummary scoresCilostazolPatients
2017
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease
Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, Cardenas J, Werner M, Brodmann M, Mustapha JA, Mena-Hurtado C, Jaff MR, Holden AH, Lyden SP, Mewissen M, Katzen B, Nanjundappa A, Khuddus M, Ricci J, Fry D, Shishehbor M, Bosarge C, Kovach R, Goodwin M, Raja M, Mayeda G, Sandhu J, Rosales O, Crowder W, Paolini D, Henretta J, Desai P, Farhat N, Kang E, Ansel G, Ghani M, Miller W, Pollock C, Korngold E, Angle J, Schultz G, Gensler T, Lopez L, Park J, Al-Khoury G, Joels C, Metzger C. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease. Circulation 2017, 136: 1102-1113. PMID: 28729250, PMCID: PMC5598919, DOI: 10.1161/circulationaha.117.028893.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleFemaleFemoral ArteryHalf-LifeHumansKaplan-Meier EstimateMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProspective StudiesSeverity of Illness IndexSingle-Blind MethodTime FactorsTreatment OutcomeVascular PatencyConceptsDrug-coated balloonsPrimary safety end pointSafety end pointTarget lesion revascularizationLesion revascularizationPrimary patencyEnd pointFemoropopliteal diseaseClinical outcomesPivotal studiesDifferent drug-coated balloonsPrimary effectiveness end pointStellarex drug-coated balloonTarget limb major amputationEffectiveness end pointAnkle-brachial indexProcedure-related deathsFemoropopliteal artery diseasePrimary patency rateDrug-Coated BalloonKaplan-Meier estimatesPaclitaxel plasma concentrationsQuality of lifeDCB cohortMajor amputation
2013
The link between vasculogenic erectile dysfunction, coronary artery disease, and peripheral artery disease: role of metabolic factors and endovascular therapy.
Meller SM, Stilp E, Walker CN, Mena-Hurtado C. The link between vasculogenic erectile dysfunction, coronary artery disease, and peripheral artery disease: role of metabolic factors and endovascular therapy. Journal Of Invasive Cardiology 2013, 25: 313-9. PMID: 23735361.Peer-Reviewed Original ResearchConceptsPeripheral artery diseaseCoronary artery diseaseVasculogenic erectile dysfunctionErectile dysfunctionArtery diseaseEndovascular therapyMetabolic factorsPathophysiology of EDArtery size hypothesisIncident clinical eventsPelvic arterial anatomyLarge prospective studiesCommon risk factorsQuality of lifeDiagnostic imaging modalitiesMacrovascular diseasePercutaneous revascularizationEndothelial dysfunctionDiabetes mellitusPathophysiological linkProspective studyArterial anatomyClinical eventsCurrent therapiesRisk factors